5 unknown, 2 completed, 2 not yet recruiting, 1 terminated. 4 Phase 4, 3 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 4 | Unknown 2, Not yet recruiting 1, Terminated 1 |
| Phase 3 | 3 | Completed 1, Not yet recruiting 1, Unknown 1 |
| Phase 2 | 2 | Completed 1, Unknown 1 |
Follow flumatinib: new trials by email Literature Review of flumatinib trials Research Report on flumatinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP HS-10382, Imatinib, Dasatinib - Chronic Myeloid Leukemia | Phase 3 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 408 | 2026-12-01 | 2026-10-21 |
| Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients Azacitidine, Venetoclax, Flumatinib - Philadelphia Chromosome, Acute Myeloid Leukemia | Phase 2 | Completed | The First Affiliated Hospital of Soochow University | 20 | 2022-05-01 | 2024-04-25 |
| A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Flumatinib, Imatinib - CML, Chronic Phase | Phase 4 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2400 | 2022-04-30 | 2022-05-10 |
| Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL Flumatinib, Imatinib - Acute Leukemia | Phase 4 | Terminated | Institute of Hematology & Blood Diseases Hospital, China | 39 | 2021-09-16 | 2025-05-01 |
| The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients Flumatinib, Dasatinib - Chronic Myeloid Leukemia in Chronic Phase | Phase 4 | Unknown | Shenzhen Second People's Hospital | 118 | 2021-07-01 | 2022-07-27 |
| Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure Flumatinib - Flumatinib, Chronic Myeloid Leukemia, Chronic Phase | Phase 4 | Unknown | Shenzhen Second People's Hospital | 200 | 2021-01-01 | 2022-03-16 |
| Evaluating Efficacy and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia(CML-CP) Without Optimal Response (Warning,Failure) to Imatinib or Dasatinib Flumatinib, Nilotinib - CML-CP; Mutation;Suboptimal Response or Failure in TKI | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 200 | 2020-11-01 | 2023-08-01 | |
| Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL Flumatinib - Acute Lymphocytic Leukemia, Adult B-Cell, BCR-ABL1 Fusion Protein Expression | Phase 3 | Unknown | Zhongda Hospital | 28 | 2020-03-01 | 2022-03-24 |
| The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML Flumatinib 600mg qd, Imatinib 400mg qd - CML, CML-CP,MMR,TKI | Phase 3 | Completed | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 400 | 2014-06-01 | 2018-02-27 |
| A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia flumatinib, imatinib - Myelogenous Leukemia, Chronic | Phase 2 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 150 | 2011-08-01 | 2013-04-10 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Leukemia, Myeloid, Chronic-Phase (2) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Myeloid (1) · Leukemia, Myeloid, Acute (1) · Neoplasm, Residual (1) · Philadelphia Chromosome (1)
Jiangsu Hansoh Pharmaceutical Co., Ltd. (3) · Shenzhen Second People's Hospital (2) · Institute of Hematology & Blood Diseases Hospital, China (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · The First Affiliated Hospital of Soochow University (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) · Zhongda Hospital (1)
China (10)
Fengkui Zhang, Dr. (1) · Jianxiang Wang, Dr. (1) · Jun Ma (1) · Xiaowen Tang, Ph.D (1) · Xin Du, Phd (1) · Zheng Ge, PhD. MD. (1)